Anne M. Traynor, MD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthDr. Traynor is an Associate Professor of Medicine in the Section of Medical Oncology in the UW Carbone Cancer Center. She specializes in the care of patients with lung cancer and in patients with head and neck malignancies. Dr. Traynor obtained an undergraduate degree in Chemical Engineering from North Carolina State University and medical degree from the University of North Carolina. She completed her residency and chief residency in internal medicine at the Mary Imogene Bassett Hospital in Cooperstown, NY. Dr. Traynor obtained her Fellowship training in medical oncology from the University of Iowa Hospitals and Clinics, and participated in the UW Carbone Cancer Center Academic Clinical Oncologist Training Program. She has been on faculty at the UW Carbone Cancer Center since 2002.
Specialties
UW Health Clinics
Hospital Affiliation(s)
University of Wisconsin Hospital and Clinics (primary)
Veterans Hospital - Wm. S. Middleton Memorial (secondary)
Languages Spoken
| English |
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
UW School of Medicine and Public Health
| Department of Medicine |
Professional Certifications and Education
| Board Certification |
Medical Oncology
|
| Fellowship |
University of Iowa Hospitals and Clinics, Iowa City
|
| Residency |
Mary Imogene Bassett Hospital, Cooperstown, NY
|
| Medical School |
University of North Carolina
|
Programs & Conditions
| Research |
Dr. Traynor leads the lung cancer research program within the UW Department of Medicine, and is the Co-Director for the Thoracic Malignancies Research Group for the UW Carbone Cancer Center. She conducts clinical trials testing new compounds in lung cancer and in early phase drug development. She collaborates with laboratory scientists in lung cancer-related translational research projects, such as examining molecular causes or resistance to radiation and systemic anti-cancer agents. Since 2003, Dr. Traynor has led the Wisconsin Oncology Network, a statewide medical oncology research group that conducts phase II clinical trials at the UW Carbone Cancer Center and at 17 other regional sites. She chairs the UW Carbone Cancer Center Data and Safety Monitoring Committee and represents the Cancer Center in several federal oncology research organizations. |
PubMed Articles
-
Gustafson DH Dubenske LL Namkoong K Hawkins R Chih MY Atwood AK Johnson R Bhattacharya A Carmack CL Traynor AM Campbell TC Buss MK Govindan R Schiller JH Cleary JF .
An eHealth system supporting palliative care for patients with non-small cell lung cancer: A randomized trial. Cancer. 2013 May 1;119(9):1744-51
[PubMed ID: 23355273]
-
Traynor AM Weigel TL Oettel KR Yang DT Zhang C Kim K Salgia R Iida M Brand TM Hoang T Campbell TC Hernan HR Wheeler DL .
Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Apr 26;
[PubMed ID: 23628526]
-
Loconte NK Holen KD Schelman WR Mulkerin DL Deming DA Hernan HR Traynor AM Goggins T Groteluschen D Oettel K Robinson E Lubner SJ .
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2012 Dec 21;
[PubMed ID: 23263993]
-
O'Mahar SE Campbell TC Hoang T Seo S Kim K Larson MM Marcotte SM LoConte NK Traynor AM .
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011 May;6(5):951-3
[PubMed ID: 21623267]
-
Traynor AM Thomas JP Ramanathan RK Mody TD Alberti D Wilding G Bailey HH .
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. Invest New Drugs. 2011 Apr;29(2):316-22
[PubMed ID: 19997959]
-
Kolesar J Brundage RC Pomplun M Alberti D Holen K Traynor A Ivy P Wilding G .
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients. Cancer Chemother Pharmacol. 2011 Feb;67(2):393-400
[PubMed ID: 20440618]
-
Traynor AM Hewitt M Liu G Flaherty KT Clark J Freedman SJ Scott BB Leighton AM Watson PA Zhao B O'Dwyer PJ Wilding G .
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Feb;67(2):305-14
[PubMed ID: 20386909]
-
Kruser TJ Traynor AM Wheeler DL .
The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients. Expert Opin Investig Drugs. 2011 Feb;20(2):305-7
[PubMed ID: 21204748]
-
Kolesar JM Sachidanandam K Schelman WR Eickhoff J Holen KD Traynor AM Alberti DB Thomas JP Chitambar CR Wilding G Antholine WE .
Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. Exp Ther Med. 2011 Jan;2(1):119-123
[PubMed ID: 21373381]
-
Traynor AM Gordon MS Alberti D Mendelson DS Munsey MS Wilding G Gammans RE Read WL .
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Invest New Drugs. 2010 Aug;28(4):509-15
[PubMed ID: 19434370]
-
Traynor AM Richards GM Hartig GK Khuntia D Cleary JF Wiederholt PA Bentzen SM Harari PM .
Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. Head Neck. 2010 May;32(5):599-606
[PubMed ID: 19757422]
-
Traynor AM Lee JW Bayer GK Tate JM Thomas SP Mazurczak M Graham DL Kolesar JM Schiller JH .
A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs. 2010 Feb;28(1):91-7
[PubMed ID: 19238328]
-
Kolesar J Huang W Eickhoff J Hahn K Alberti D Attia S Schelman W Holen K Traynor A Ivy P Wilding G .
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol. 2009 Jun;64(1):79-86
[PubMed ID: 18941749]
-
Attia S Morgan-Meadows S Holen KD Bailey HH Eickhoff JC Schelman WR Traynor AM Mulkerin DL Campbell TC McFarland TA Huie MS Cleary JF Tevaarwerk AJ Alberti DB Wilding G Liu G .
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51
[PubMed ID: 18841362]
-
Schelman WR Morgan-Meadows S Marnocha R Lee F Eickhoff J Huang W Pomplun M Jiang Z Alberti D Kolesar JM Ivy P Wilding G Traynor AM .
A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009 May;63(6):1147-56
[PubMed ID: 19082825]
-
Traynor AM Dubey S Eickhoff JC Kolesar JM Schell K Huie MS Groteluschen DL Marcotte SM Hallahan CM Weeks HR Wilding G Espinoza-Delgado I Schiller JH .
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol. 2009 Apr;4(4):522-6
[PubMed ID: 19347984]
-
Traynor AM Schiller JH Stabile LP Kolesar JM Eickhoff JC Dacic S Hoang T Dubey S Marcotte SM Siegfried JM .
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer. 2009 Apr;64(1):51-9
[PubMed ID: 18701186]
-
Attia S Traynor AM Kim K Merchant JJ Hoang T Ahuja HG Beatty PA Hansen RM Masters GA Oettel KR Shapiro GR Larson MM Larson ML Schiller JH .
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol. 2008 Sep;3(9):1018-25
[PubMed ID: 18758305]
-
Liu G Kolesar J McNeel DG Leith C Schell K Eickhoff J Lee F Traynor A Marnocha R Alberti D Zwiebel J Wilding G .
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors. Clin Cancer Res. 2008 May 1;14(9):2732-9
[PubMed ID: 18451239]
-
Kolesar JM Schelman WR Geiger PG Holen KD Traynor AM Alberti DB Thomas JP Chitambar CR Wilding G Antholine WE .
Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine. J Inorg Biochem. 2008 Apr;102(4):693-8
[PubMed ID: 18061679]
-
Bailey HH Mahoney MR Ettinger DS Maples WJ Fracasso PM Traynor AM Erlichman C Okuno SH .
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. Cancer. 2006 Nov 15;107(10):2462-7
[PubMed ID: 17058289]
